Being a consultant for BMY didn't stop Prof. Eggermont from stressing the autoimmune toxicities of anti-CTLA4 agents (and the danger to patients with clinical or subclinical autoimmune disease), at the 11th World Congress on Cancers of the Skin. Btw, he was the lead investigator of the EORTC's ganglioside GM2-KLH vaccine failed (has been halted early) trial in melanoma.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.